Staying hydrated, eating protein-rich foods, and managing portion sizes minimize discomfort
We already know from two-year follow-up studies of patients who have taken injectable GLP-1 drugs for at least six months that net weight loss in the real world is as little as 4.7% for many reasons, including poor adherence as a result of side effects, supply and affordability
Medication and interaction review Daily dosing education Insurance and pharmacy availability review Ongoing response and tolerance monitoring Nutrition and Meal-Replacement Plans Medication is paired with an eating plan that supports protein intake, calorie control, metabolic health and sustainable habits
Cold or room-temperature foods may be better tolerated than hot meals
Better glycemic control is still the goal in diabetes to prevent microvascular disease
Saxenda on the NHS Saxenda (liraglutide) was previously available on the NHS through specialist services and some pilot schemes